Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients

Infection

Volumn 37, Issue 5, 2009, Pages 424-431

  Riethmueller, J ^a   Ballmann, M ^c   Schroeter, T W ^b   Franke, P ^a   Von Butler, R ^a   Claass, A ^b   Junge, S ^c   Doering, G ^d   Stern, M ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CEFTAZIDIME; IMMUNOGLOBULIN G; TOBRAMYCIN;

ADOLESCENT; ADULT; ARTICLE; BODY WEIGHT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; HEARING IMPAIRMENT; HUMAN; LEUKOCYTE COUNT; LUNG FIBROSIS; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; PRESCHOOL CHILD; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SINGLE DRUG DOSE; SPUTUM ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; CYSTIC FIBROSIS; FEMALE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; PNEUMONIA, BACTERIAL; PSEUDOMONAS INFECTIONS; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 70350173917     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-009-8117-4     Document Type: Article

References (35)

1. C. Schaedel I. de Monestrol L. Hjelte M. Johannesson R. Kornfält A. Lindblad B. Strandvik L. Wahlgren L. Holmberg 2002 Predictors of deterioration of lung function in cystic fibrosis Pediatr Pulmonol. Pediatr Pulmonol 33 483 491 1:STN:280:DC%2BD383oslOgug%3D%3D
2. M.H. Schoeni C. Casaulta-Aebischer 2000 Nutrition and lung function in cystic fibrosis patients: review Clin Nutr 19 79 85 10.1054/clnu.1999.0080 (Pubitemid 30316020)
3. G. Steinkamp B. Wiedemann 2002 Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project Thorax 57 596 601 10.1136/thorax.57.7.596 1:STN:280:DC%2BD38zltlWhuw%3D%3D 12096202 (Pubitemid 34761761)
4. G. Doering S.P. Conway H.G. Heijerman M.E. Hodson N. Hoiby A. Smyth D.J. Touw 2000 Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus Eur Respir J 16 749 767 10.1034/j.1399-3003.2000.16d30.x (Pubitemid 30834538)
5. Stern M, Sens B, Wiedemann B, Busse O, Wenzlaff P: Qualitä tssicherung Mukoviszidose 2002. Überblick über den Gesundheitszustand der Patienten in Deutschland. Zentrum für Qualitätsmanagement im Gesundheitswesen. Einrichtung der Ärztekammer: Niedersachsen, 2003.
6. N. Høiby 2000 Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis Paediatr Drugs 2 451 463 10.2165/00128072-200002060-00004 11127845
7. J.S. Elborn R.J. Prescott B.H. Stack M.C. Goodchild J. Bates C. Pantin N. Ali D.J. Shale M. Crane 2000 Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs Thorax 55 355 358 10.1136/thorax.55.5.355 1:STN:280:DC%2BD3c3jtl2gsA%3D%3D 10770814 (Pubitemid 30245690)
8. L. Breen N. Aswani 2001 Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis Cochrane Database Syst Rev 4 CD002767 11687159
9. T. Marco O. Asensio M. Bosque J. de Gracia C. Serra 2000 Home intravenous antibiotics for cystic fibrosis Cochrane Database Syst Rev 4 CD001917 11034733
10. J. Riethmueller A. Busch V. Damm R. Ziebach M. Stern 2002 Home and hospital antibiotic treatment prove similarly effective in cystic fibrosis Infection 30 387 391 10.1007/s15010-002-2095-0 1:STN:280:DC%2BD38jhsFymug%3D%3D 12478330 (Pubitemid 35447470)
11. M. Barza J.P. Ioannidis J.C. Cappelleri J. Lau 1996 Single or multiple daily doses of aminoglycosides: a meta-analysis Br Med J 312 338 345 1:CAS:528:DyaK28Xhslams78%3D (Pubitemid 26049400)
12. R.D. Bates M.C. Nahata J.W. Jones K. McCoy G. Young S. Cox W.J. Barson 1997 Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis Chest 112 1208 1213 10.1378/chest.112.5.1208 1:CAS:528:DyaK2sXnsFSqurk%3D 9367459 (Pubitemid 27497850)
13. U. Heininger B. Boewing K. Stehr W. Solbach 1993 [Aminoglycosides in patients with mucoviscidosis and pulmonary exacerbation: comparison of once or three times daily administration] TT-Aminoglykoside bei Patienten mit Mukoviszidose und pulmonaler Exazerbation: Vergleich von Einmal- und Dreimalgabe Klin Paediatr 205 18 22 10.1055/s-2007-1025191 1:STN:280:DyaK3s7ovVensA%3D%3D
14. P. Vic S. Ategbo D. Turck M.O. Husson V. Launay G.A. Loeuille A. Sardet A. Deschildre D. Druon C. Arrouet-Lagande 1998 Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for Pseudomonas exacerbations in cystic fibrosis Arch Dis Child 78 536 539 10.1136/adc.78.6.536 1:STN:280:DyaK1cznvVKgsw%3D%3D 9713009 (Pubitemid 28274695)
15. A. Whitehead S.P. Conway C. Etherington N.A. Caldwell N. Setchfield S. Bogle 2002 Once-daily tobramycin in the treatment of adult patients with cystic fibrosis Eur Respir J 19 303 309 10.1183/09031936.02.00221602 1:CAS:528:DC%2BD38XitVKnsr4%3D 11866010 (Pubitemid 34162832)
16. A. Smyth K.H. Tan P. Hyman-Taylor M. Mulheran S. Lewis D. Stableforth A. Knox T.S. Group 2005 Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis-the TOPIC study: a randomised controlled trial Lancet 365 573 578 1:CAS:528:DC%2BD2MXhtlSgt7k%3D 15708100
17. G. Doering H.J. Obernesser K. Botzenhart B. Flehmig N. Hoiby A. Hofmann 1983 Proteases of Pseudomonas aeruginosa in patients with cystic fibrosis J Infect Dis 147 744 750
18. A. Bauernfeind R.M. Bertele K. Harms G. Horl K. Jungwirth C. Petermueller B. Przyklenk C. Weisslein-Pfister 1987 Qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis Infection 15 270 277 10.1007/BF01644137 1:STN:280:DyaL1c%2FjtFOnug%3D%3D 3117700
19. J.E. Hoppe U. Theurer-Mainka M. Stern 1995 Comparison of three methods for culturing throat swabs from cystic fibrosis patients J Clin Microbiol 33 1896 1898 1:STN:280:DyaK2MzpsFShtw%3D%3D 7665666
20. P.H. Quanjer 1983 Standardized lung function testing: report working Party "standardization of lung function tests", European Community for Coal and Steel Bull Eur Physiopathol Respir 19 1 95
21. Zapletal A, Samanek M, Paul T: Lung function in children and adolescents. methods, reference values. Karger, Basel, 1987.
22. S. Cunningham J.R. McColm A. Mallinson I. Boyd T.G. Marshall 2003 Duration of effect of intravenous antibiotics on spirometry and sputum cytokines in children with cystic fibrosis Pediatr Pulmonol 36 43 48 10.1002/ppul.10311 12772222 (Pubitemid 36734765)
23. S. Glass N.D. Plant D.A. Spencer 2005 The effects of intravenous tobramycin on renal tubular function in children with cystic fibrosis J Cyst Fibros 4 221 225 10.1016/j.jcf.2005.09.003 1:CAS:528:DC%2BD2MXht1OlsbbE 16239129 (Pubitemid 43013028)
24. P.G. Ambrose S.M. Bhavnani C.M. Rubino A. Louie T. Gumbo A. Forrest G.L. Drusano 2007 Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore Clin Infect Dis 44 79 86 10.1086/510079 1:CAS:528:DC%2BD2sXnvVCjtA%3D%3D 17143821 (Pubitemid 44968990)
25. D.G. Contopoulos-Ioannidis N.D. Giotis D.V. Baliatsa J.P. Ioannidis 2004 Extended-interval aminoglycoside administration for children: a meta-analysis Pediatrics 114 e111 e118 10.1542/peds.114.1.e111 15231982
26. K. Tan H. Bunn 2000 Once daily versus multiple daily dosing with intravenous aminoglycosides for cystic fibrosis Cochrane Database Syst Rev 4 CD002009 11034740
27. P.M. Beringer A.A. Vinks R.W. Jelliffe B.J. Shapiro 2000 Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration Antimicrob Agents Chemother 44 809 813 10.1128/AAC.44.4.809-813. 2000 1:CAS:528:DC%2BD3cXitFOltLs%3D 10722474 (Pubitemid 30165253)
28. R.D. Moore C.R. Smith P.S. Lietman 1984 The association of aminoglycoside plasma levels with mortality in patients with Gramnegative bacteremia J Infect Dis 149 443 448 1:STN:280:DyaL2c7oslSltA%3D%3D 6715900
29. R.M. Shawar D.L. MacLeod R.L. Garber J.L. Burns J.R. Stapp C.R. Clausen S.K. Tanaka 1999 Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis Antimicrob Agents Chemother 43 2877 2880 1:CAS:528:DyaK1MXnvVCqsb4%3D 10582875
30. A. Aminimanizani P.M. Beringer J. Kang L. Tsang R.W. Jelliffe B.J. Shapiro 2002 Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis J Antimicrob Chemother 50 553 559 10.1093/jac/dkf168 1:CAS:528:DC%2BD38XotVSjtbg%3D 12356801
31. K. Bartel T. Habash S. Lugauer H. Barmeier B. Bowing M. Unsal C. Schoerner U. Heininger 1999 Optimal tobramycin dosage in patients with cystic fibrosis-evidence for predictability based on previous drug monitoring Infection 27 268 271 10.1007/s150100050027 1:CAS:528:DC%2BD3cXmsVyjsA%3D%3D 10885841 (Pubitemid 29443685)
32. R. Bragonier N.M. Brown 1998 The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis J Antimicrob Chemother 42 103 106 10.1093/jac/42.1.103 1:CAS:528:DyaK1cXltFOru7Y%3D 9700537 (Pubitemid 28356370)
33. B. Vogelman S. Gudmundsson J. Turnidge J. Leggett W.A. Craig 1988 In vivo postantibiotic effect in a thigh infection in neutropenic mice J Infect Dis 157 287 298 1:CAS:528:DyaL1cXhtVGqu7Y%3D 3121761
34. A. Kumar M.B. Hay G.A. Maier J.W. Dyke 1992 Post-antibiotic effect of ceftazidime, ciprofloxacin, imipenem, piperacillin and tobramycin for Pseudomonas cepacia J Antimicrob Chemother 30 597 602 10.1093/jac/30.5.597 1:CAS:528:DyaK3sXpslyqtA%3D%3D 1283606
35. G. Steinkamp M. Lutge U. Wurster J.G. Schulz-Baldes H.J. Grone J.H. Ehrich 1986 Renal function in cystic fibrosis: proteinuria and enzymuria before and after tobramycin therapy Eur J Pediatr 145 526 531 10.1007/BF02429057 1:STN:280:DyaL2s7jtlKruw%3D%3D 2880721 (Pubitemid 17041456)